Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT
Kenneth A. Iczkowski(University of California, Davis), Rodolfo Montironi(Marche Polytechnic University), Wei Huang(University of Florida), Roberta Mazzucchelli(University of Foggia), Gary Stevens(University of Florida), Cooley G. Pantazis(Mayo Clinic)
Cited by 25
Related Papers
Classification of renal cell carcinoma
|Cancer|1997|878
The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma
|The American Journal of Surgical Pathology|2020|705
Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study
|The Lancet Oncology|2020|631
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
|Modern Pathology|2017|404
Cell-Free DNA in Human Blood Plasma
|Pancreas|1998|381